Cargando…

Immunogenicity and Antiviral Response of Therapeutic Hepatitis B Vaccination in a Mouse Model of HBeAg-Negative, Persistent HBV Infection

During the natural course of chronic hepatitis B virus (HBV) infection, the hepatitis B e antigen (HBeAg) is typically lost, while the direct transmission of HBeAg-negative HBV may result in fulminant hepatitis B. While the induction of HBV-specific immune responses by therapeutic vaccination is a p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kosinska, Anna D., Festag, Julia, Mück-Häusl, Martin, Festag, Marvin M., Asen, Theresa, Protzer, Ulrike
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402308/ https://www.ncbi.nlm.nih.gov/pubmed/34451966 http://dx.doi.org/10.3390/vaccines9080841

Ejemplares similares

Correlations of HBV Genotypes, Mutations Affecting HBeAg Expression and HBeAg/ anti-HBe Status in HBV Carriers
por: Lim, Chee Kent, et al.
Publicado: (2006)

Viral Biomarkers in Chronic HBeAg Negative HBV Infection
por: Hadziyannis, Emilia, et al.
Publicado: (2018)

Correlation Between HBsAg Quantitation and HBV DNA in HBeAg-Negative HBV/D Patients
por: Teriaky, Anouar, et al.
Publicado: (2013)

The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore
por: Lacey, L F, et al.
Publicado: (2007)

HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients
por: Song, Guangjun, et al.
Publicado: (2023)

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients
por: Yang, Jiezuan, et al.
Publicado: (2014)

Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
por: Song, Byung-Cheol, et al.
Publicado: (2014)

Differential Plasma MicroRNA Profiles in HBeAg Positive and HBeAg Negative Children with Chronic Hepatitis B
por: Winther, Thilde Nordmann, et al.
Publicado: (2013)

Study on pathological and clinical characteristics of chronic HBV infected patients with HBsAg positive, HBV DNA negative, HBeAg negative
por: Zeng, Zhan, et al.
Publicado: (2023)

HBsAg isoform dynamics during NAP‐based therapy of HBeAg‐negative chronic HBV and HBV/HDV infection
por: Bazinet, Michel, et al.
Publicado: (2022)

Prevalent HBeAg-negative HBV DNA-positive Chronic Hepatitis B Individuals in Bangladesh
por: Rashed Ul Islam, SM, et al.
Publicado: (2021)

Expanding antiviral therapy indications for HBeAg-negative chronic hepatitis B patients with normal ALT and positive HBV DNA
por: Zhou, Jing, et al.
Publicado: (2022)

Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B
por: Svicher, Valentina, et al.
Publicado: (2021)

Serum HBeAg and HBV DNA levels are not always proportional and only high levels of HBeAg most likely correlate with high levels of HBV DNA: A community-based study
por: Chen, Ping, et al.
Publicado: (2017)

Impact of Drug-Resistance Polymerase Mutations on the Replication of HBeAg-Positive and HBeAg-Negative Hepatitis B Virus Strains in Vitro
por: Tacke, Frank, et al.
Publicado: (2012)

Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase
por: Lee, Hye Won, et al.
Publicado: (2020)

Is the function of the HBeAg really unknown?
por: Milich, David R.
Publicado: (2019)

Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection
por: Kosinska, Anna D., et al.
Publicado: (2019)

Antiviral therapy leads to histological improvement of HBeAg-negative chronic hepatitis B patients
por: Papachrysos, Nikolaos, et al.
Publicado: (2015)

Antiviral therapy leads to histological improvement in HBeAg-negative chronic hepatitis B patients
por: Basyigit, Sebahat, et al.
Publicado: (2015)

Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients
por: Keshvari, Maryam, et al.
Publicado: (2015)

Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in The Gambia
por: Mendy, Maimuna E, et al.
Publicado: (2008)

Analysis of clinical and virologic features in Hepatitis B e Antigen (HbeAg)-negative and HbeAg-positive Egyptian chronic hepatitis B patients
por: Fouad, Rabab, et al.
Publicado: (2020)

Quantitative HBsAg versus HBV DNA in Predicting Significant Hepatitis Activity of HBeAg-Positive Chronic HBV Infection
por: Zhang, Zhanqing, et al.
Publicado: (2021)

The Intracellular HBV DNAs as Novel and Sensitive Biomarkers for the Clinical Diagnosis of Occult HBV Infection in HBeAg Negative Hepatocellular Carcinoma in China
por: Wang, Hui, et al.
Publicado: (2014)

Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver
por: Bae, Sung Kwan, et al.
Publicado: (2012)

Manifestations of Perihepatic Lymph Nodes in Acute Flare of Chronic Hepatitis B: Association with HBeAg Status and with HBeAg Seroconversion
por: Ko, Yen-Ling, et al.
Publicado: (2015)

Characteristics of an Outpatient Cohort with HBeAg-Negative Chronic Hepatitis B
por: Dimzova, Marija, et al.
Publicado: (2019)

A model to predict liver damage in patients with HBeAg-positive chronic HBV infection
por: Maiocchi, Laura, et al.
Publicado: (2021)

Increased Coffee Intake Reduces Circulating HBV DNA and HBsAg Levels in HBeAg-Negative Infection: A Cohort Study
por: Chook, Jack Bee, et al.
Publicado: (2019)

HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B
por: Zhang, Chong, et al.
Publicado: (2020)

A cautionary note to hepatitis B e antigen (HBeAg)‐negative test results in pregnant women in an area prevalent of HBeAg‐negative chronic hepatitis B
por: Chalid, Maisuri T., et al.
Publicado: (2022)

HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients
por: Yang, Song, et al.
Publicado: (2016)

Evaluation of serum HBV viral load, transaminases and histological features in chronic HBeAg-negative hepatitis B patients
por: Esmaeelzadeh, Abbas, et al.
Publicado: (2017)

ACE Score Identifies HBeAg-negative Inactive Carriers at a Single-point Evaluation, Regardless of HBV Genotype
por: Roade, Luisa, et al.
Publicado: (2022)

Serum sphingolipid levels associate with upcoming virologic events and HBV genotype D in a cohort of patients with HBeAg-negative HBV infection
por: Mücke, Victoria Therese, et al.
Publicado: (2018)

Different interventional criteria for chronic hepatitis B pregnant women with HBeAg(+) or HBeAg(-): Epidemiological data from Shaanxi, China
por: Chen, Tianyan, et al.
Publicado: (2018)

Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study
por: Yang, Xiaoling, et al.
Publicado: (2017)

Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL
por: Yao, Chih-Chien, et al.
Publicado: (2017)

Phenotypes of peripheral CD4(+) T helper cell subsets in pregnant women with HBeAg-negative chronic asymptomatic HBV carriers
por: Feng, Guofang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3ms4dut0btps2899ssghgolpvu